• Exceptional Weight Loss

    Clinical trials show 15-22% average weight loss - more than any other medication

  • Heart Health Benefits

    Improves cardiovascular health while managing diabetes effectively

  • FDA Approved

    Latest breakthrough technology approved for both diabetes and weight management

Tirzepatide represents the latest breakthrough in weight management and diabetes treatment. As a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it offers unprecedented results for patients seeking effective, long-term solutions.

Real Patient Success:

"I lost 45 pounds in 6 months with Tirzepatide. My energy is back, my diabetes is under control, and I feel like myself again." - Sarah M.

Mechanism of Action

  • GLP-1 Receptor Activation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying
  • GIP Receptor Activation: Enhances insulin sensitivity and may have direct effects on fat metabolism
  • Appetite Regulation: Acts on brain receptors to reduce appetite and food intake
  • Gastric Motility: Slows gastric emptying, leading to increased satiety

Transformative Results

  • Diabetes Management:

    • Significant reduction in HbA1c levels
    • Improved glycemic control
    • Low risk of hypoglycemia
    • Cardiovascular benefits

  • Weight Management Success:

    • Average weight loss of 15-22% in clinical trials
    • Sustained weight reduction
    • Improved body composition
    • Reduction in waist circumference

  • Clinical Trial Highlights:

    In the SURMOUNT trials, patients achieved an average of 20.9% weight loss at the highest dose - results that exceeded all expectations and set new standards in weight management therapy.

Dosing and Administration

  • Route: Subcutaneous injection once weekly

    Starting Dose: 2.5 mg once weekly for 4 weeks

    Injection Sites: Thigh, abdomen, or upper arm. Rotate injection sites weekly.

  • Maintenance Doses:

    • 5 mg once weekly (minimum effective dose)
    • 7.5 mg once weekly
    • 10 mg once weekly
    • 12.5 mg once weekly
    • 15 mg once weekly (maximum dose)

Side Effects

  • Common (≥5%):

    • Nausea (12-18%)
    • Diarrhea (12-16%)
    • Vomiting (6-12%)
    • Constipation (6-7%)
    • Abdominal pain (6-9%)
    • Injection site reactions

  • Serious (Rare):

    • Pancreatitis
    • Gallbladder disease
    • Kidney problems
    • Severe hypoglycemia (when combined with insulin/sulfonylureas)
    • Thyroid C-cell tumors (theoretical risk)

Contraindications and Precautions

  • Contraindications

    • Personal or family history of medullary thyroid carcinoma
    • Multiple Endocrine Neoplasia syndrome type 2
    • Known hypersensitivity to tirzepatide

  • Use with Caution:

    • History of pancreatitis
    • Severe renal impairment
    • Diabetic retinopathy
    • Pregnancy and breastfeeding